 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSK completes $2B acquisition of Bellus Health

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON, June 28, 2023 LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK...

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

Canadian biotech stock BELLUS Health has been snatched from the public market. However, these two biopharma growth stocks also have the capacity to change healthcare.
The post These Canadian Biotech Stocks Are Quietly Changing the Face of Healthcare appeared first on The Motley Fool Canada.

Early ...

These Canadian Biotech Stocks Are Quietly Changing the Face of Healthcare

GSKs share price spiked on news of a settlement over Zantac, but other factors also mean it may continue to recover losses from its high this year.
The post Will GSKs share price spike on Zantac news be sustained? appeared first on The Motley Fool UK.

GSKs (LSE: GSK) share price rose on Friday 23 ...

Will GSK's share price spike on Zantac news be sustained?

Shares of BELLUS Health Inc. (TSX:BLU  Get Rating) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$19.34 and traded as high as C$19.47. BELLUS Health shares last traded at C$19.46, with a volume of 5,578 shares. Analyst ...

BELLUS Health (TSX:BLU) Shares Pass Above Fifty Day Moving Average of $19.34

Shares of BELLUS Health Inc. (NASDAQ:BLU  Get Rating) saw an uptick in trading volume on Wednesday . 2,825,233 shares traded hands during trading, a decline of 9% from the previous sessions volume of 3,099,651 shares.The stock last traded at $14.72 and had previously closed at $14.73. ...

BELLUS Health (NASDAQ:BLU) Sees Large Volume Increase

Over the last three days, A.I.dvisor has detected that BLU's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For ...

BELLUS Health (BLU, $14.74) Aroon Indicator entered an Uptrend on June 22, 2023.

Canadian stocks are underperforming their American peers as commodity prices retreat. The closely-watched S&P/TSX Composite index dropped to a low of $19,572 on Friday, meaning it has fallen by over 6% from the highest level this year. In contrast, its American counterparts like the S&P 500 and ...

Canada's TSX Composite index could retreat to C$19,200

BELLUS Health (BLU, $14.72) Aroon Indicator entered an Uptrend on June 21, 2023.

BELLUS Health Inc. (NASDAQ:BLU  Get Rating) saw a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 7,590,000 shares, a growth of 6.2% from the May 15th total of 7,150,000 shares. Based on an average daily volume of 4,610,000 ...

BELLUS Health Inc. (NASDAQ:BLU) Short Interest Up 6.2% in May

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

Watchers	6,689
52-Wk Low	$6.38
52-Wk High	$14.76

Market Cap	$2.47B
Volume (M)	102,860.00
52-Wk High	$14.76
52-Wk Low	$6.38

Period	Estimated	Reported	Surprise	Result
Q2'23	$-0.21	--	--	N/A
Q1'23	$-0.19	$-0.20	-5.26%	MISSED
Q4'22	$-0.20	$-0.15	23.50%	BEAT
Q3'22	$-0.17	$-0.20	-18.52%	MISSED
Q2'22	$-0.17	$-0.18	-6.67%	MISSED

BLU Bellus Health Inc

About

Feed

News

Earnings

Fundamentals